MiMedx Projects 2026 Net Sales of $250M-$260M and Targets 20% Adjusted EBITDA Margin
MiMedx Group, Inc. (MDXG) has provided long-term financial guidance, projecting net sales between $250 million and $260 million for the year 2026. The company is focusing on operational efficiency with a specific target of achieving an adjusted EBITDA margin exceeding 20% through its strategic initiatives. CEO Joseph Capper noted that third-quarter results reinforce the current strategic direction of the firm. This guidance follows recent organizational shifts and aims to demonstrate a clear path toward improved profitability and scaled revenue growth for the biotechnology company.
Tickers: $MDXG
Topics: management outlook quarterly earnings strategic direction
Read the full article at Seeking Alpha
Part of the story Simpson Manufacturing Co. Targets 20% to 20.5% Operating Margin for 2026 (2 articles)